Effect of suplatast tosilate on cough variant asthma

A 40-year-old female patient with chronic persistent cough was diagnosed with cough variant asthma (CVA). To investigate the effect of suplatast tosilate (suplatast, 300 mg/day, three times a day), cough scores, medication scores, pulmonary function, capsaicin cough threshold, bronchial hyperrespons...

Full description

Saved in:
Bibliographic Details
Published in:Allergology international 2000, Vol.49 (1), p.89-92
Main Authors: Shioya, Takanobu, Kagaya, Manabu, Sano, Masaaki, Ito, Takeshi, Shindo, Tsutomu, Kashima, Masayuki, Watanabe, Akiko, Sato, Kazuhiro, Ito, Nobuaki, Sasaki, Masahiro, Miura, Mamoru
Format: Article
Language:English
Subjects:
asthma
capsaicin
cough threshold
cough variant asthma
eosinophilic cationic protein
suplatast
T helper 2 cell-derived cytokine inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 40-year-old female patient with chronic persistent cough was diagnosed with cough variant asthma (CVA). To investigate the effect of suplatast tosilate (suplatast, 300 mg/day, three times a day), cough scores, medication scores, pulmonary function, capsaicin cough threshold, bronchial hyperresponsiveness (BHR) to methacholine and eosinophilic cationic protein (ECP) concentration in hypertonic saline-induced sputum were evaluated before and after a 6-week treatment with suplatast. Treatment with suplatast resulted in a marked decrease in persistent cough and in the percentage of eosinophils and ECP concentration in induced sputum. It also resulted in a marked improvement in capsaicin cough threshold and a slight improvement in BHR. These results suggest that suplatast tosilate may be useful for treating patients with CVA.
ISSN:1323-8930
1440-1592
DOI:10.1046/j.1440-1592.2000.00164.x